Oxford, U.K. 5 February 2021 : Sensyne Health plc (LSE: SENS) ( Sensyne or the Company or the Group ), the UK Clinical AI company, announces that it has appointed Hina Zaman as Managing Director of its Healthcare Division and Martin Gouldstone as Chief Business Officer of its Life Sciences Division. Hina Zaman joins Sensyne from Babylon Health, where as Product Director she led the company s global product for value-based care and previously its global product proposition in the women s health space. Prior to that, Hina founded the UK s first virtual care platform for women s health, pioneering a new model of personalised, proactive care for health consumers. Hina has extensive experience as a healthcare management consultant, leading change initiatives across the NHS commissioning and provider landscape while at Finnamore Ltd. (now part of GE Healthcare), and in US healthcare systems while at Deloitte
Oxford, UK; 21 January 2021: Sensyne Health plc (LSE: SENS) ( Sensyne or the Company or the Group ), the UK Clinical AI company, today announces its Interim Results for the six months ended 31 October 2020. I am pleased to report that Sensyne has made significant commercial progress over the past six months and has achieved several key milestones in the development of its research partnerships with NHS Trusts and in its work for leading pharmaceutical companies applying Clinical AI to improve patient care and accelerate life sciences research. I am particularly pleased with the results we have been able to achieve during the COVID-19 pandemic.
Sensyne Health plc: Sensyne Health Launches First Digital Health Product in the U.S.
Sensyne Health plc (LSE: SENS) ( Sensyne or the Company or the Group ), the British Clinical AI technology company, today announces that it has launched GDm-Health, its remote monitoring solution for diabetes in pregnancy, in the U.S. with immediate effect.
Sensyne s sales and marketing partner for the U.S., Cognizant, is now offering the solution to U.S. health systems and health plans via its sales force. Virtual care services powered by GDm-Health will qualify for reimbursement under remote patient monitoring codes introduced by the Centers for Medicare and Medicaid Services (CMS) in 2020.
Sensyne Health Launches First Digital Health Product in the U.S.
OXFORD, England–(BUSINESS WIRE)–Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the British Clinical AI technology company, today announces that it has launched GDm-Health, its remote monitoring solution for diabetes in pregnancy, in the U.S. with immediate effect.
Sensyne’s sales and marketing partner for the U.S., Cognizant, is now offering the solution to U.S. health systems and health plans via its sales force. Virtual care services powered by GDm-Health will qualify for reimbursement under remote patient monitoring codes introduced by the Centers for Medicare and Medicaid Services (CMS) in 2020.